医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

R-Tech Ueno: The End of a Phase 3 Clinical Study and Preliminary Findings from a Phase 3 of Unoprostone (Development Code UF-021) for Treatment of Retinitis Pigmentosa

2015年03月09日 PM03:45
このエントリーをはてなブックマークに追加


 

TOKYO

R-Tech Ueno (JASDAQ: 4573) announced today the end of a Phase 3 clinical study with Unoprostone (development code UF-021) ophthalmic solution that are being developed in our company for the treatment of retinitis pigmentosa and the preliminary Findings from a Phase 3.

The Phase 3 clinical study with UF-021 ophthalmic solution for treatment of retinitis pigmentosa (ClinicalTrials.gov Identifier:NCT01786395), for which an effective therapy has not been currently established, was a multicenter study using a placebo (without the active ingredient) as a control carried out based on Good Clinical Practice (GCP) in patients with visual field constriction and then deterioration of vision. This was a randomized double-masked controlled study for 52 weeks for efficacy, followed by the open trial study of UF-021 for a further 52 weeks for safety. The target sample size was 180 patients and the study was carried out at 38 sites nationwide.

The primary endpoint of the study was the changes in the value of the mean retinal sensitivity at four central points through HFA (10-2). The difference compared to the placebo group was not statistically significant.

However, the primary endpoint and visual acuity of UF-021 group demonstrated improvement compared to Day 0 (before the study) and the difference was statistically significant. On the other hand, the Goldmann visual field of the placebo group progressed statistically and significantly the constriction of the visual field compared to Day 0. Furthermore the total score of VFQ-25 was found to have improved statistically and significantly in the UF-021 group.

We confirmed the therapeutic effectiveness of UF-021 ophthalmic solution for Retinitis Pigmentosa through the present Phase 3 clinical study in Japan, but as the primary endpoint at the end of study was not statistically significant, we are analyzing the data from various angles and examining possibility of the new drug application to MHLW as best we can now. And we decided to close the open trial study of UF-021 for a further 52 weeks for safety in the view of objectivity of the data obtained.

Regarding the impact of this matter on the company’s full-year results, no changes are to be made on the full-year business result forecasts released on February 12, 2015.

For full details of the press release, please visit:
http://www.rtechueno.com/en/investor/press/documents/150309_pr_en.pdf

CONTACT

R-Tech Ueno, Ltd.
Koji Nakamura, +81-3-3596-8011
Director
Business
Management Department
info@rtueno.co.jp

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease